(Q38024305)

English

Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review

scientific article published on 05 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review (English)

1 reference

Europe PubMed Central

27 August 2017

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

John Hornberger

1

1 reference

Europe PubMed Central

27 August 2017

Michael D Alvarado

2

1 reference

Europe PubMed Central

27 August 2017

Chien Rebecca

3

1 reference

Europe PubMed Central

27 August 2017

Hialy R Gutierrez

4

1 reference

Europe PubMed Central

27 August 2017

Tiffany M Yu

5

1 reference

Europe PubMed Central

27 August 2017

William J Gradishar

6

1 reference

Europe PubMed Central

27 August 2017

language of work or name

0 references

publication date

5 July 2012

1 reference

Europe PubMed Central

27 August 2017

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

27 August 2017

104

1 reference

Europe PubMed Central

27 August 2017

14

1 reference

Europe PubMed Central

27 August 2017

1068-1079

1 reference

Europe PubMed Central

27 August 2017

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Commercialized multigene predictors of clinical outcome for breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Gene expression profiling of breast cancer: a new tumor marker

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Clinical utility of the 70-gene MammaPrint profile in a Japanese population.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Use of a genomic test (MammaPrint™) in daily clinical practice to assist in risk stratification of young breast cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

The influence of a gene expression profile on breast cancer decisions

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

A decision aid to assist in adjuvant therapy choices for breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS261

21 January 2018

Identifiers

10.1093/JNCI/DJS261

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38024305&oldid=1737909868"